Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER)

We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis and haemostasis 2016-09, Vol.116 (3), p.472-479
Hauptverfasser:	Kucher, Nils, Aujesky, Drahomir, Beer, Jürg H, Mazzolai, Lucia, Baldi, Thomas, Banyai, Martin, Hayoz, Daniel, Kaeslin, Thomas, Korte, Wolfgang, Escher, Robert, Husmann, Marc, Frauchiger, Beat, Baumgartner, Iris, Spirk, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Anticoagulants - adverse effects Anticoagulants - therapeutic use Factor Xa Inhibitors - adverse effects Factor Xa Inhibitors - therapeutic use Female Hemorrhage - chemically induced Humans Male Middle Aged Pulmonary Embolism - drug therapy Registries Retrospective Studies Rivaroxaban - adverse effects Rivaroxaban - therapeutic use Switzerland Thrombolytic Therapy Treatment Outcome Venous Thromboembolism - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We investigated three-month clinical outcomes in patients with venous thromboembolism (VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice. Between November 2012 and February 2015, 2,062 consecutive patients with VTE from 11 acute care hospitals in Switzerland were enrolled in the SWIss Venous ThromboEmbolism Registry (SWIVTER). Overall, 417 (20 %) patients were treated with rivaroxaban. In comparison to 1,645 patients on conventional anticoagulation, patients on rivaroxaban were younger (56 ± 18 vs. 65 ± 17 years; p
ISSN:	0340-6245 2567-689X
DOI:	10.1160/TH16-03-0209